
CBL-154 identity review
CBL-154 is included here because it appears in the supplied product brief, but a reliable identity and commercial specification have not been established for publication. It should not be described as a cheaper or less potent version of CBL-514 without direct evidence. Similar naming is not a chemical relationship, a development-stage comparison or proof of a shared manufacturer.
If you are evaluating material under this name, provide the original specification, supplier identity and supporting source. A useful review checks the exact substance or formulation, identifiers, intended laboratory use, analytical methods and batch documentation. Requested packaging amounts can be discussed only after that definition is clear. The accompanying vial is a design concept with no brand, verified batch or availability claim. This page preserves the enquiry route while keeping uncertainty visible. For a sequence-defined custom peptide, use the separate synthesis service so the proposed material can be reviewed on its own technical terms.
- Identity: awaiting a reliable primary specification.
- Sequence, CAS, molecular formula and purity: not assigned.
- 20 mg, 50 mg and 100 mg: possible enquiry targets only.
- No potency, price or clinical relationship claimed.





